TGFβ and IL10 have an impact on risk group and prognosis in childhood ALL

Pediatric Blood and Cancer

Volumn 62, Issue 1, 2015, Pages 72-79

  Winkler, B ^a   Taschik, J ^a   Haubitz, I ^a   Eyrich, M ^a   Schlegel, P G ^a   Wiegering, V ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

ALL; Cytokine; Paediatric; Polymorphism; Prognosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CODON; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FLOW CYTOMETRY; FOLLOW UP; GENETICS; METABOLISM; MORTALITY; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

CASE-CONTROL STUDIES; CHILD; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922809755     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25142     Document Type: Article

References (32)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371:1030-1043.
2. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukaemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95:3310-3322.
3. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukaemia. Semin Hematol 2009; 46:52-63.
4. Ansari M, Sauty G, Labuda M, et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukaemia. Blood 2009; 114:1383-1386.
5. Eyrich M, Wiegering V, Lim A, et al. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia-A prospective study of 20 paediatric patients. Br J Haematol 2009; 147:360-370.
6. Wiegering V, Frank J, Freudenberg S, et al. Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukaemia. Leuk Lymphoma 2014; 55:870-875.
7. de Deus DM, Lugo KA, Muniz MT. Influence of IL10 (G 1082 A) and TNFalpha (G308A) polymorphisms on the survival of pediatric patients with ALL. Leuk Res Treatment 2012; 2012:692348.
8. Gao LB, Pan XM, Jia J, et al. IL-8-251A/T polymorphism is associated with decreased cancer risk among population-based studies: Evidence from a meta-analysis. Eur J Cancer 2010; 46:1333-1343.
9. Xue H, Wang YC, Lin B, et al. A meta-analysis of interleukin-10-592 promoter polymorphism associated with gastric cancer risk. PloS one 2012; 7:e39868.
10. Lippitz BE. Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol 2013; 14:e218-228.
11. Dai L, Gast A, Horska A, et al. A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer 2009; 52:819-823.
12. Perrey C, Pravica V, Sinnott PJ, et al. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: A technical report. Transpl Immunol 1998; 6:193-197.
13. Wiegering V, Eyrich M, Wunder C, et al. Age-related changes in intracellular cytokine expression in healthy children. Eur Cytokine Netw 2009; 20:75-80.
14. Cox ED, Hoffmann SC, DiMercurio BS, et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72:720-726.
15. Sobti RC, Berhane N, Mahedi SA, et al. Polymorphisms of IL-6 174 G/C, IL-10 -592 C/A and risk of HIV/AIDS among North Indian population. Mol Cell Biochem 2010; 337:145-152.
16. Warle MC, Farhan A, Metselaar HJ, et al. Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transpol 2003; 9:170-181.
17. Chenjiao Y, Zili F, Haibin C, et al. IL-10 promoter polymorphisms affect IL-10 production and associate with susceptibility to acute myeloid leukaemia. Pharmazie 2013; 68:201-206.
18. Luczynski W, Stasiak-Barmuta A, Ilendo E, et al. Low expression of costimulatory molecules and mRNA for cytokines are important mechanisms of immunosuppression in acute lymphoblastic leukaemia in children? Neoplasma 2006; 53:301-304.
19. Franchimont D, Martens H, Hagelstein MT, et al. Tumour necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: Potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999; 84:2834-2839.
20. Wilson AG. Genetics of tumour necrosis factor (TNF) in autoimmune liver diseases: Red hot or red herring? J Hepatol 1999; 30:331-333.
21. Lauten M, Matthias T, Stanulla M, et al. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukaemia 2002; 16:1437-1442.
22. Mascher B, Schmitt W, Csernok E, et al. Polymorphisms in the tumor necrosis factor genes in Wegener's granulomatosis. Exp Clin Immunogenet 1997; 14:226-233.
23. Wiegering V, Eyrich M, Rutkowski S, et al. TH1 predominance is associated with improved survival in pediatric medulloblastoma patients. Cancer Immunol Immunother 2011; 60:693-703.
24. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306.
25. Shah R, Selby ST, Yokley B, et al. TNF, LTA and TGFB1 genotype distributions among acute graft-vs-host disease subsets after HLA-matched unrelated hematopoietic stem cell transplantation: A pilot study. Tissue Antigens 2009; 74:50-56.
26. Perrey C, Brenchley PE, Johnson RW, et al. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol 1998; 6:101-106.
27. Sheen YY, Kim MJ, Park SA, et al. Targeting the transforming growth factor-beta signalling in cancer therapy. Biomolecules Ther 2013; 21:323-331.
28. Galon J, Angell HK, Bedognetti D, et al. The continuum of cancer immunosurveillance: Prognostic, predictive and mechanistic signatures. Immunity 2013; 39:11-26.
29. Spisak S, Galamb B, Sipos F, et al. Applicability of antibody and mRNA expression microarrays for identifying diagnostic and progression markers of early and late stage colorectal cancer. Dis Markers 2010; 28:1-14.
30. Wallace A, Kapoor V, Sun J, et al. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 2008; 14:3966-3974.
31. Massague J. TGFbeta Cancer Cell 2008; 134:215-230.
32. Wiegering V, Winkler B, Haubitz I, et al. Lower TGFss serum levels and higher frequency of IFNgamma-producing T cells during early immune reconstitution in surviving children after allogeneic stem cell transplantation. Pediatr Blood Cancer 2013; 60:121-128.